Immunai

We are a multidisciplinary team of immunologists, engineers, drug developers, computer scientists, and entrepreneurs focused on bringing breakthrough medicines to patients. Built from the ground up with an engineering-first approach to biology and an unparalleled understanding of the immune system, we know we’re up for the challenge. Immunai was founded in December 2018. Our global team spans New York City, Tel Aviv, San Francisco, Prague, and Zurich.

In March 2021, Immunai acquired Dropprint Genomics, a Y-combinator backed, single cell genomics software company based in San Francisco. Dropprint’s database of immune cells further expanded AMICA.

In July 2021, Immunai made the transformational acquisition of NEBION, a world leader in biocuration and data integration. NEBION has structured hundreds of thousands of samples and millions of cells across thousands of public studies under a unified clinical ontology, all powered by bespoke expert curation. This data has supercharged AMICA’s growth and expanded our target discovery efforts into a wide range of inflammatory and oncological settings.